Clinical Trials · NCT02807233
Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Ipsen
- Enrollment
- 115
- Start date
- Jul 2016
- Locations
- 39 sites, Portugal, Spain
- Primary endpoint
- Percentage of subjects with a normal Insulin-like Growth Factor 1 (IGF-1) level in the assay before the study visit.